Onyx Pharmaceuticals, Inc. (MM) (ONXX) Quote

NEW$ out...Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Intraday Stock Chart
Today : Tuesday 1 October 2013


THOUSAND OAKS, Calif., Oct. 1, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $125 per share in cash. As announced on Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash. The tender offer expired at 12:00 midnight New York City time on Oct. 1, 2013. Amgen expects to complete the acquisition of Onyx later today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.

"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world," said Robert A. Bradway, chairman and chief executive officer of Amgen. "We look forward to working together with the talented staff at Onyx to make the most of our exciting oncology portfolio and pipeline."

As of the expiration of the tender offer, approximately 57,698,132 shares were validly tendered and not withdrawn in the tender offer, representing approximately 78.5 percent of Onyx's outstanding shares, according to the depositary for the tender offer. The condition to the tender offer that a majority of Onyx's outstanding shares on a fully-diluted basis be validly tendered and not withdrawn has been satisfied. As a result, Amgen has accepted for payment and will promptly pay for all validly tendered shares.

As a result of the merger planned to be effected later today, all remaining eligible Onyx shares will be converted into the right to receive $125 per share in cash, without interest and less any applicable withholding taxes, the same price that was paid in the tender offer (eligible shares exclude those for which holders properly demanded appraisal under Delaware law and those held by Amgen or Onyx or their respective wholly owned subsidiaries). Following completion of the merger, Onyx shares will cease to be traded on the NASDAQ Global Market, which is expected to take effect later today.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward Looking Statements

This news release contains forward-looking statements that are based on Amgen's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements about the planned completion of the tender offer and the merger, estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to Amgen's business. Unless otherwise noted, Amgen is providing this information as of Oct. 1, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Risks and uncertainties include whether the proposed transaction described in this press release can be completed in a timely manner, and whether the anticipated benefits of the proposed transaction can be achieved. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Amgen develops product candidates internally and through licensing collaborations, partnerships, joint ventures and acquisitions. Product candidates that are derived from relationships or acquisitions may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with Amgen's products after they are on the market. Amgen's business may be impacted by government investigations, litigation and product liability claims. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, it could become subject to significant sanctions. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products. In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen's products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products. In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for its products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products. Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on Amgen's business and results of operations.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen


Copyright 2013 PR Newswire

Interesting article on biggest pharma deals including Onyx



http://www.earningsimpact.com/Ideaz/50/With-%2435-Billion-in-Deals%2c-2013-among-Biggest-Years-of-Pharma-Acquisitions-so-far#sthash.MbLk8fjY.dpbs

Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Onyx
PR NewswirePress Release: Amgen – 15 hours ago

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Sept. 18, 2013 /PRNewswire/ -- Amgen (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Amgen's proposed acquisition of Onyx, was terminated early on Sept. 18, 2013, by the United States Federal Trade Commission. The waiting period was scheduled to expire on Sept. 23, 2013.
(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)
(Logo: http://photos.prnewswire.com/prnh/20130825/LA69117LOGO)
As previously announced on Aug. 25, 2013, Amgen and Onyx entered into an agreement under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash, with the transaction to be effected through a tender offer. The termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer. Other closing conditions remain to be satisfied, including, among others, a minimum tender of at least a majority of outstanding Onyx shares on a fully diluted basis.
The tender offer is scheduled to expire at 12:00 midnight, New York City time, on Oct. 1, 2013 (one minute after 11:59 p.m., New York City time, on Sept. 30, 2013), unless it is extended pursuant to and in accordance with the terms of the merger agreement between Amgen and Onyx. The complete Offer to Purchase dated Sept. 3, 2013, related to the tender offer has been filed with the U.S. Securities and Exchange Commission and can be viewed online at www.sec.gov.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

the deal is done

CBMG buyout after AMGN buyout of ONYX???

If CBMG gets approval for liver and/or knee osteoarthritis clinical trials in China, they will get bought by a big biopharm company for big bucks.

ONXX Nice news!

Another man's trash is another man's treasure.

ONXX

what do you think now?? still a waste?

Amgen getting ready to scoop up Onyx for 10.5 billion. Today Onyx, one day CTIX. From NYTimes: Amgen is close to a deal to buy Onyx Pharmaceuticals Inc., a maker drugs to fight cancer, for about $10.5 billion, people briefed on the matter said on Saturday. A deal — in which Amgen would pay about $125 a share — could be announced as soon as Monday, though these people cautioned that talks are continuing and could still fall apart. If a transaction is completed, it would be the latest of many in the health care industry, especially as drug makers look to add to their offerings. One attractive set of products is new cancer drugs, which can fetch high prices. Amgen is the world’s largest biotechnology company by sales, with $17.3 billion in revenue last year. But its top-selling products are older and many are selling more slowly, or even declining. Some of the company’s drugs are also facing competition in Europe from near-generic copies, known as biosimilars, and that competition is expected to come to the United States in the next few years. Teva is expected to introduce a near-copy of Amgen’s Neupogen, a drug that helps prevent infections in patients undergoing chemotherapy, late this year. A deal for Onyx would be the first big takeover struck by Robert A. Bradway, who became Amgen’s chief executive in May of last year. Analysts expected Mr. Bradway, who spent most of his career as an investment banker at Morgan Stanley, to drive a tough bargain. Amgen began its quest for Onyx in June, when it made an unsolicited bid valued at $120 a share, about 38 percent above the stock price at the time. But Onyx rebuffed the approach and hired the investment bank Centerview Partners to seek bids for the company. A number of drug makers expressed interest, including Pfizer and Novartis, but analysts considered Amgen the most likely buyer. Onyx’s main attraction is its cancer drugs, two of which won approval last year. Its crown jewel is Kyprolis, a drug for multiple myeloma that was approved in July and that Onyx fully owns. Several analysts expect annual sales of Kyprolis to reach $2 billion within several years, providing tremendous impetus to Onyx’s growth. The company reported $362.2 million in revenue in 2012, mostly from proceeds of drugs it shares with Bayer. But Kyprolis’s $61 million in sales during the second quarter were slightly below some analysts’ expectations, raising concerns about competition. Onyx also disclosed that the drug had failed to improve survival in an interim analysis of results from a clinical trial being conducted to win approval in Europe. While that does not mean the drug does not work, the company must now wait for final data from the testing, which is expected in the first half of next year. A brief hiccup in the discussions occurred recently when Amgen demanded to see more clinical trial data on Kyprolis, people briefed on the discussions have said. Amgen sought to lower its bid from the $130 a share it had floated because of that dispute. Onyx and its advisers, however, have come to the conclusion that at $125 a share, Amgen’s bid is significantly more than its original proposal and outweighs the uncertainty of a drawn-out sales process, one of the people briefed on the matter said. At $125 a share, Amgen would be paying about 13 times the amount analysts expect Onyx to have in sales over the next 12 months, one of the highest multiples in the biopharmaceutical industry. Mark Schoenebaum, a biotechnology and pharmaceutical analyst at the ISI Group, has said that many of Amgen’s largest shareholders are value investors who are interested in having the company return money to shareholders through dividends and share buybacks instead of making big acquisitions. “I think they are under a lot of pressure to not overpay,’’ he told clients this week. Tags Amgen Inc, Drugs (Pharmaceuticals), Mergers, Acquisitions and Divestitures, Onyx Pharmaceuticals Related Articles

--------------------------------------------------------------------------------


"Wide diversification is only required when investors do not understand what they are doing." - Warren Buffett

Good sales report and a red day...

Who is looking for the next Onxx? You might take a look at CYDY. They have a mono clonal anitbody to fight hiv. PPS finally starting to move, stage iib testing to start soon.

My post was for onxx.Its price is being manipulated by reuters sources.First they drove price from 136 last week to 126.
Today,a new article quoting the 3 sources says that Amgen has raised a big war chest to acquire onxx.
I think it is an attempt to scare other bidders-or at least keep price from rising.Pl.read both the article-one from last week and one from today.
If it wasn't from Bloomberg's article on 7/22 contradicting the interest from Amgen,Pfizer,Astra Zeneca and Novartis,the price of onxx would have gone down more.

Reuters sources manipulating onxx stock price.Last week,these sources told reuters that Amgen is not interested.That news drove price down from 136 to 126$/share,
Today these sources is telling reuters that Amgen has raised more cash to buy Amgen from 3 bankers.I think they are saying that Amgen is determined to buy-so stay away from bidding.These sources are gaming in favor of amgen.
Bloomberg wrote an objective article on Monday,7/22 using their sources saying there are 3 other bidders interested in onxx.
Please read these article by reuters and draw your conclusion.

Reuters sources manipulating onxx stock price.Last week,these sources told reuters that Amgen is not interested.That news drove price down from 136 to 126$/share,
Today these sources is telling reuters that Amgen has raised more cash to buy Amgen from 3 bankers.I think they are saying that Amgen is determined to buy-so stay away from bidding.These sources are gaming in favor of amgen.
Bloomberg wrote an objective article on Monday,7/22 using their sources saying there are 3 other bidders interested in onxx.
Please read these article by reuters and draw your conclusion.

Reuters sources manipulating onxx stock price.Last week,these sources told reuters that Amgen is not interested.That news drove price down from 136 to 126$/share,
Today these sources is telling reuters that Amgen has raised more cash to buy Amgen from 3 bankers.I think they are saying that Amgen is determined to buy-so stay away from bidding.These sources are gaming in favor of amgen.
Bloomberg wrote an objective article on Monday,7/22 using their sources saying there are 3 other bidders interested in onxx.
Please read these article by reuters and draw your conclusion.

Interesting remarks during Business-Update-Call

read here
http://www.earningsimpact.com/Transcript/81410/ONXX/Business-Update-Call

ONXX

ONNX and PPHM partnership would be the perfect match with their drugs being combined together. Would make their stocks ridiculous. All due with time. Alot of rumors

Oopsies, if he took that risk he could be one of the insiders...IMO (lol)

May want to read this first

https://www.sec.gov/news/press/2013/2013-123.htm

WEEEEEE!!!!!

I'm a millionaire!

Go ONXX!

Wow!! Major move today

Onyx Pharma Is For Sale, for North of $10B

BY Adam Feuerstein| 07/01/13 - 12:15 AM EDT
Stock quotes in this article: ONXX, AMGN, SNY, PFE
SOUTH SAN FRANCISCO (TheStreet) --

Onyx Pharmaceuticals (ONXX_) is in play now that Amgen's (AMGN_) $10 billion offer has been rejected as too low, so how much will it cost Amgen or another suitor to acquire the company?

Amgen's initial offer of $120 per share in cash was a 38 percent premium to Onyx's closing stock price of $86.82 on Friday. Onyx rejected the offer Sunday, saying it "significantly undervalued" the company, but also said it would seek out competitive offers from interested suitors.

Onyx is worth about $110 per share as a standalone company today, but if a competitive bidding situation ensues, the company could be acquired for as much as $148 per share, Deutsche Bank analyst Robyn Karnauskas said in a research note published Sunday.

It's common for initial takeout offers to be raised over time. Sanofi (SNY_) first bid $69 per share for Genzyme. Following negotiations between the two companies, the final acquisition price bumped up to $74 per share plus a contingent value right tied to the performance of a Genzyme drug. Likewise, Roche (RHHBY) was forced to raise initial offer for Genentech before closing the deal.

"In our opinion, this [$120 per share] offer could be Amgen's effort to bring both parties to the negotiation table," Karnauskas writes, suggesting Amgen isn't likely to give up on acquiring Onyx.

An Amgen offer for Onyx valued at $140 per share would be 5 percent dilutive to earnings in 2014 and mildly accretive in 2015, Karnauskas writes.

Onyx in partnership with the German drug firm Bayer sells the kidney and liver cancer drug Nexavar and the colon cancer drug Stivarga. On its own, Onyx sell Kyprolis, used to treat multiple myeloma.

Onyx reported 2012 revenue of $362 million. The company's revenue is expected to grow to $624 million this year, $881 million in 2014 and $1.2 billion in 2015, according to consensus analyst estimates compiled by S&P Capital IQ.

Onyx is expected to lose $1.85 per share on an adjusted basis this year but generate a profit of 51 cents per share in 2014 and $3.79 per share in 2015, according to consensus analyst estimates compiled by S&P Capital IQ.
_________________________________________________________
http://www.thestreet.com/story/11966123/1/onyx-pharma-is-for-sale-but-suitors-need-to-offer-way-more-than-10-billion.html

ONXX

Bayer Seeks US, EU Approval for Nexavar to Treat Thyroid Cancer

By Dow Jones Business News, July 01, 2013, 03:14:00 AM EDT
Vote up


Bayer AG (BAYN.XE) said Monday it is seeking approval from the U.S. and the E.U. to use its drug Nexavar to treat thyroid cancer.

MAIN FACTS:
-Nexavar, also known as sorafenib, is an oral drug developed and marketed by Bayer HealthCareand Onyx Pharmaceuticals Inc. ( ONXX ).
-The companies have applied to the U.S. Food & Drug Administration and the European Medicines Agency to use the drug to treat localized, advanced thyroid cancer or metastasis.
-"Especially for patients in the advanced stage, treatment options are lacking or very limited," Bayer's head of global development Dr. Kemal Malik said.
-Nexavar is already approved to treat liver cell cancer and advanced kidney cancer, Bayer said.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires
07-01-130314ET
Copyright (c) 2013 Dow Jones & Company, Inc.

Read more: http://www.nasdaq.com/article/bayer-seeks-us-eu-approval-for-nexavar-to-treat-thyroid-cancer-20130701-00046#ixzz2XnB7sRgU
_______________________________________________________

ONXX

Onyx Seeks Other Bidders After Rejecting Amgen Proposal

June 30, 2013, 2:27 p.m. ET

By Joseph Walker and George Stahl

Onyx Pharmaceuticals Inc. (ONXX) said it is now seeking potential buyers after rejecting an unsolicited acquisition proposal from Amgen Inc. (AMGN) that valued the maker of cancer drugs at more than $8.7 billion.

Onyx said in a statement Sunday that Amgen's offer "significantly undervalued Onyx and its prospects, and was not in the best interest of Onyx or its shareholders." Amgen's bid valued Onyx at $120 a share, or about 38% higher than its closing price Friday of $86.82.

As a result of Amgen's interest, Onyx's board has authorized its financial adviser to contact potential acquirers who may have an interest in the company. An Amgen representative wasn't immediately available.

"Onyx has tremendous momentum and, with the expansion of our pipeline and two successful product launches," said Dr. N. Anthony Coles, chairman and chief executive, in the statement. "We are actively exploring the potential to combine Onyx with another company as an option to create additional value for Onyx shareholders."

Over the past 12 months, Onyx shares have traded between $63 and $101.57. Onyx's value has grown since the approval of its blood-cancer drug Kyprolis last summer and on encouraging results regarding Nexavar for thyroid cancer.

Earlier this month, Onyx said Nexavar helped to nearly double the number of months that patients with a rare type of advanced thyroid cancer lived without their diseases worsening. Patients with treatment-resistant thyroid tumors have no other treatment options, study investigators said at the time, and if Nexavar is approved it would be the first new drug for this type of thyroid cancer in 40 years.

Bayer AG (BAYRY, BAYN.XE) is Onyx's partner on Nexavar.

Centerview Partners LLC is acting as financial adviser to Onyx, and Goodwin Procter LLP is acting as legal adviser.

Write to Joseph Walker at joseph.walker@wsj.com and George Stahl at george.stahl@wsj.com
_________________________________________________________
http://online.wsj.com/article/BT-CO-20130630-700725.html?mod=googlenews_wsj

ONXX

Onyx Pharma Rejects Unsolicited Acquisition Proposal From Amgen

6/30/2013 1:28 PM ET

Onyx Pharmaceuticals Inc. (ONXX: Quote) Sunday confirmed it received and rejected an unsolicited proposal from Amgen Inc. to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash.

The Board of Directors of Onyx had evaluated the proposal made by Amgen concluded that the price proposed by Amgen significantly undervalued Onyx and its prospects, and was not in the best interest of Onyx or its shareholders.

Onyx communicated this determination to Amgen on Friday, June 28, 2013.

Based upon expressions of interest received from other third parties and the recent proposal from Amgen, the Onyx Board has authorized its financial advisor to contact potential acquirers who may have an interest in the Company in a transaction that is in the best interest of Onyx shareholders.

Click here to receive FREE breaking news email alerts for Amgen Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com
_____________________________________________________________
http://www.rttnews.com/2143674/onyx-pharma-rejects-unsolicited-acquisition-proposal-from-amgen.aspx

ONXX

Report Claims Amgen Made Bid For Onyx Pharma

BY Adam Feuerstein| 06/28/13 - 06:23 PM EDT
Stock quotes in this article: AMGN, ONXX

THOUSAND OAKS, Calif. (TheStreet) --

Amgen (AMGN_) has reportedly made an unsolicited, $120-per-share takeover offer for Onyx Pharmaceuticals (ONXX_), according to the Financial Post, citing an Amgen offer letter obtained by the Canadian newspaper.

Onyx shares jumped 19% to $107.50 in Friday after-market trading. Onyx spokeswoman Lori Melancon had no comment, saying she hadn't yet read the Financial Post story and had only just talked to the reporter who wrote it.

Amgen spokesman David Caouette would not confirm nor deny the authenticity of the letter. "We don't comment on market rumors or speculation," he said.

"I feel a timely combination of our organizations would be very complementary," said the letter allegedly written by Amgen to Onyx two weeks ago, according to the Financial Post story. The letter goes on to propose an Amgen acquisition of Onyx for $120 per share, or $10 billion in total.

The Financial Post doesn't disclose the author of the letter, nor does the newspaper say how it obtained the letter.

Amgen shares were unchanged at $96.88 in after-hours trading.

-- Reported by Adam Feuerstein in Boston.
_________________________________________________________
http://www.thestreet.com/_nasdaq/story/11965940/1/report-claims-amgen-made-bid-for-onyx-pharma.html?&cm_ven=NASDAQ&cm_cat=FREE&cm_ite=NA

ONXX

Don't see the news but ONXX is trading up ~30% to ~$110-111 after hours. Popped at about 5:30. Associated with the takeout rumor < http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89474441 >

ONXX

Bayer cancer drug recommended in EU

LONDON, Fri Jun 28, 2013 7:58am EDT
(Reuters) -

Experts at the European Medicines Agency have recommended approval of Bayer's drug Stivarga for the treatment of metastatic colorectal cancer.

Friday's positive decision from EMA's Committee for Medicinal Products for Human Use (CHMP) follows an earlier green light for the product in the United States.

Stivarga is a pill that works by blocking several enzymes that promote cancer growth.

Under an agreement signed in 2011, Onyx Pharmaceuticals will receive a 20 percent royalty payment on global sales of Stivarga.

Bayer and Onyx jointly market Stivarga in the United States, while Bayer has sole marketing rights in the rest of the world.
______________________________________________________________
http://www.reuters.com/article/2013/06/28/bayer-europe-cancer-idUSL5N0F03AA20130628

ONXX

Onyx benefiting from mention in this article?

Quote:
__________________________________________________
Buybacks and Acquisitions, Not Deleveraging, Are Part of Key Cash Deployment Strategy

Reducing debt hasn't been the greatest point of emphasis for most health-care firms, considering their strong cash flows and manageable leverage. Buybacks remain the preferable cash deployment strategy outside of acquisitions and reinvestments, although their pace has decelerated as of late. With growth prospects still uncertain given the macro environment in the U.S. and Europe, cheap debt remains the key source of capital to fund growth strategies, particularly acquisitions. We believe Big Pharma firms will probably continue to rummage around biotechnology for their next targets, and our top five biotech takeout targets all offer the combination of highly sought factors: pipeline potential, therapeutic area attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx (ONXX), (other 4 omitted)
_________________________________________________________
http://news.morningstar.com/articlenet/article.aspx?id=600175

ONXX

Onyx benefiting from mention in this article?

Quote:
__________________________________________________
Buybacks and Acquisitions, Not Deleveraging, Are Part of Key Cash Deployment Strategy

Reducing debt hasn't been the greatest point of emphasis for most health-care firms, considering their strong cash flows and manageable leverage. Buybacks remain the preferable cash deployment strategy outside of acquisitions and reinvestments, although their pace has decelerated as of late. With growth prospects still uncertain given the macro environment in the U.S. and Europe, cheap debt remains the key source of capital to fund growth strategies, particularly acquisitions. We believe Big Pharma firms will probably continue to rummage around biotechnology for their next targets, and our top five biotech takeout targets all offer the combination of highly sought factors: pipeline potential, therapeutic area attractiveness, collaborative fit, and digestible size. Our top biotech picks are Onyx (ONXX), (other 4 omitted)
_________________________________________________________
http://news.morningstar.com/articlenet/article.aspx?id=600175

ONXX

ONXX among analysts' top undervalued stocks:

http://www.optioncast.com/stock-options-blog/analyst-opinions/undervalued/

ONXX

A much more simple than your in the ibox but bought in this morning based on the chart and analysts' valuations:



ONXX

You are crazy trying to predict ONXX price movements using Ouija boards.

ONXX: BEARISH DARK CLOUD COVER

Definition

This is a top reversal pattern with two candlesticks. A white candlestick appears on the first day while an uptrend is in progress. The second day opens at a new high, with a gap up and closes more than halfway into the prior white body, leading to the formation of a strong black candlestick.
Recognition Criteria

1. The market is characterized by a prevailing uptrend.
2. A white candlestick appears on the first day.
3. A black candlestick opens on the second day with a gap up and closes more than halfway into the body of the first day.
4. The second day fails to close below the body of the first day.

Pattern Requirements and Flexibility
The first day of the Bearish Dark Cloud Cover pattern is a normal or long white candlestick. The second day should open well above the close of the first day and close more than halfway into the prior white candlestick’s body. However, the close of the second day must stay inside the body of the first day.

Trader’s Behavior
The market moves in an uptrend. The first white body reinforces this view. The next day the market opens higher via a gap, showing that the bullishness still persists. After this very bullish open, bears decide to take the lead. The market plunges toward the close, prices start to go down resulting in a close way below the previous day’s close. Now the bulls are losing their confidence and are reevaluating their long positions. The potential short sellers start thinking that new highs may not hold and perhaps it is time to take short positions.

Sell/Stop Loss Levels
The confirmation level is defined as the last close. Prices should cross below this level for confirmation.

The stop loss level is defined as the last high. Following the bearish signal, if prices go up instead of going down, and close or make two consecutive daily highs above the stop loss level, while no bullish pattern is detected, then the stop loss is triggered.

ONXX: Analysis from StockTA...........$$$

Analysis Overall Short Intermediate Long
Bullish (0.44) Bullish (0.44) Bullish (0.46) Bullish (0.42)

Read more at http://www.stockta.com/cgi-bin/analysis.pl?symb=ONXX&cobrand=&mode=stock#fUXFpJy0tDQGCwQp.99

ONXX Chart: Bearish Dark Cloud Cover reversal pattern formed today off the century mark......might see a pullback to MA's(10 & 20).......

SAR flipped to a Buy Signal on Mon.......Bearish pattern developed after a 6 day run..........yesterday's close above 100 was huge.......may need to reload in order to turn it into Support.........need to see a close above April 23rd HOD to avoid a Double Top.......

ONXX on bounce off MA's(10 & 20) & continue to run Radar..........$$$

ONXX News: Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual Meeting
Print
Alert
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Intraday Stock Chart
Today : Wednesday 15 May 2013



Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection, and Stivarga® (regorafenib) tablets across a range of cancers. These presentations will take place at the 49th American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, 2013, in Chicago, IL.
"The data being presented at ASCO add to the depth of our understanding of how these medicines work across tumor types and treatment settings," said Pablo Cagnoni, M.D., Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. "We are committed to exploring therapies in difficult-to-treat cancers for patients who have limited treatment options."

Nexavar® (sorafenib) tablets

Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The Phase 3 DECISION trial

Dr. Marcia Brose, University of Pennsylvania Health System, United States
Sunday, June 2, 2013
Oral Presentation: 3:20 - 3:35 p.m., N Hall B1
Plenary Session - Special Sessions, Core Sessions
Abstract # 4
Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in > 3000 Sor-treated patients (pts): clinical findings in pts with liver dysfunction

Dr. Jorge Marrero, University of Michigan, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Noncolorectal) Cancer
Abstract # 4126
Kyprolis® (carfilzomib) for Injection

Final results from the Phase 1b/2 study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma

Dr. Michael Wang, MD Anderson Cancer Center, United States
Monday, June 3, 2013
Poster viewing: 1:15 - 5:15 p.m., E450b
Poster discussion: 4:45 - 5:45 p.m., E354b
Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster #9
Abstract # 8529
Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a Phase (Ph) 1/2 trial

Dr. Cyrille Touzeau, University of Nantes, France
Monday, June 3, 2013
Oral Presentation: 9:15 - 9:30 a.m., E Arie Crown Theater
Oral abstract session - Myeloma
Abstract # 8513
Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM)

Dr. Shebli Atrash, University of Arkansas for Medical Sciences, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Lymphoma and Plasma Cell Disorders
Abstract # 8595
Results of a Phase 1/2 study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)

Dr. James R. Berenson, Institute for Myeloma & Bone Cancer Research, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Lymphoma and Plasma Cell Disorders
Abstract # 8599
Results of a Phase 1 trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)

Dr. Jennifer Ann Woyach, Ohio State University, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Leukemia, Myelodysplasia, and Transplantation
Abstract # 7077
Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up

Dr. Andrzej J. Jakubowiak, University of Chicago, United States
Monday, June 3, 2013
Poster viewing: 1:15 - 5:15 p.m., E450b
Poster discussion: 4:45 - 5:45 p.m., E354b
Poster discussion session - Lymphoma and Plasma Cell Disorders, Poster #23
Abstract # 8543
Stivarga® (regorafenib) tablets

Mutational analysis of plasma DNA from patients (pts) in the Phase 3 GRID study of regorafenib (REG) vs placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes

Dr. George Demetri, Dana-Farber Cancer Institute, United States
Monday, June 3, 2013
Oral Presentation: 3:45 - 4:00 p.m., S100bc
Oral abstract session - Sarcoma
Abstract # 10503
Results from a Phase 3 trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): subgroup analysis of outcomes based on pretreatment characteristics

Dr. Heikki Joensuu, Helsinki University Central Hospital, Finland
Saturday, June 1, 2013
Poster viewing: 1:15 - 5:00 p.m., S Hall A2
General poster session - Sarcoma
Abstract # 10551
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: an ongoing randomized, double-blind, Phase 3 trial

Dr. Ann-Lii Cheng, National Taiwan University Hospital, Taipei
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Noncolorectal) Cancer
Abstract # TPS4163 (Trials in Progress)
Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the Phase 3 CORRECT study

Dr. Axel Grothey, Mayo Clinic, United States
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Colorectal) Cancer
Abstract # 3637
Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): analysis of age subgroups in the Phase 3 CORRECT trial

Dr. Eric van Cutsem, University Hospital Leuven in Gasthuisberg, Belgium
Sunday, June 2, 2013
Poster viewing: 8:00 - 11:45 a.m., S Hall A2
General poster session - Gastrointestinal (Colorectal) Cancer
Abstract # 3636
Analysis of plasma protein biomarkers from the CORRECT Phase 3 study of regorafenib for metastatic colorectal cancer

Dr. Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, United States
Tuesday, June 4, 2013
Poster viewing: 8:00 - 12:00 p.m., S405
Poster discussion: 11:30 - 12:30 p.m., S406
Poster discussion session - Gastrointestinal (Colorectal) Cancer, Poster #6
Abstract # 3514
About Nexavar® (sorafenib) Tablets

Nexavar is approved in the U.S. for the treatment of patients with unresectable hepatocellular carcinoma and for the treatment of patients with advanced renal cell carcinoma. Nexavar is thought to inhibit both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to inhibit multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) -- two important processes that enable cancer growth. These kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in more than 100 countries. Nexavar is also being evaluated by Bayer and Onyx, international study groups, government agencies and individual investigators in a range of cancers.

Important Safety Considerations For Nexavar® (sorafenib) Tablets

Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction.

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar.

Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, if required.

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Nexavar should be discontinued if Stevens-Johnson Syndrome or toxic epidermal necrolysis are suspected as these may be life threatening.

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar. Discontinue Nexavar in the event of a gastrointestinal perforation.

Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time (PT), International Normalized Ratio (INR) or clinical bleeding episodes.

Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures.

Nexavar in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer.

The safety and effectiveness of Nexavar has not been established in patients with non-small cell lung cancer.

Nexavar can prolong the QT/QTc interval and increase the risk for ventricular arrhythmias.

Avoid use in patients with congenital long QT syndrome and monitor patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.

Drug-induced hepatitis with Nexavar may result in hepatic failure and death. Liver function tests should be monitored regularly and in cases of increased transaminases without alternative explanation Nexavar should be discontinued.

Nexavar may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while on Nexavar and female patients should also be advised against breastfeeding while receiving Nexavar.

Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar.

Avoid concomitant use of strong CYP3A4 inducers, when possible, because inducers can decrease the systemic exposure of Nexavar. Nexavar exposure decreases when coadministered with oral neomycin. Effects of other antibiotics on Nexavar pharmacokinetics have not been studied.

Most common adverse reactions reported for Nexavar-treated patients vs. placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs. 25%), fatigue (46% vs. 45%), abdominal pain (31% vs. 26%), weight loss (30% vs. 10%), anorexia (29% vs. 18%), nausea (24% vs. 20%), and hand-foot skin reaction (21% vs. 3%). Grade 3/4 adverse reactions were 45% vs. 32%.

Most common adverse reactions reported for Nexavar-treated patients vs. placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs. 13%), rash/desquamation (40% vs. 16%), fatigue (37% vs. 28%), hand-foot skin reaction (30% vs. 7%), alopecia (27% vs. 3%), and nausea (23% vs. 19%). Grade 3/4 adverse reactions were 38% vs. 28%.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar-us.com or call 1.866.NEXAVAR (1.866.639.2827).

Indication and Important Safety Information for Kyprolis® (carfilzomib) for Injection

Kyprolis™ (carfilzomib) for Injection is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.

The safety of KYPROLIS was evaluated in clinical studies of 526 patients with relapsed and/or refractory multiple myeloma.

Death due to cardiac arrest has occurred within a day of KYPROLIS administration. New onset or worsening of pre-existing congestive heart failure with decreased left ventricular function or myocardial ischemia have occurred following administration of KYPROLIS. Cardiac failure events (e.g., cardiac failure congestive, pulmonary edema, ejection fraction decreased) were reported in 7% of patients. Monitor for cardiac complications and manage promptly. Withhold KYPROLIS for Grade 3 or 4 cardiac events until recovery and consider whether to restart KYPROLIS based on a benefit/risk assessment. Patients with New York Heart Association Class III and IV heart failure, myocardial infarction in the preceding 6 months, and conduction abnormalities uncontrolled by medications may be at greater risk for cardiac complications.

Pulmonary arterial hypertension (PAH) was reported in 2% of patients treated with KYPROLIS and was Grade 3 or greater in less than 1% of patients. Evaluate with cardiac imaging and/or other tests as indicated. Withhold KYPROLIS for pulmonary hypertension until resolved or returned to baseline and consider whether to restart KYPROLIS based on a benefit/risk assessment.

Dyspnea was reported in 35% of patients enrolled in clinical trials. Grade 3 dyspnea occurred in 5%; no Grade 4 events, and 1 death (Grade 5) was reported. Monitor and manage dyspnea immediately; interrupt KYPROLIS until symptoms have resolved or returned to baseline.

Infusion reactions were characterized by a spectrum of systemic symptoms, including fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina. These reactions can occur immediately following infusion or up to 24 hours after administration of KYPROLIS. Administer dexamethasone prior to KYPROLIS to reduce the incidence and severity of reactions. Inform patients of the risk and symptoms, and to contact physician if symptoms of an infusion reaction occur.

Tumor lysis syndrome (TLS) occurred following KYPROLIS administration in < 1% of patients. Patients with multiple myeloma and a high tumor burden should be considered to be at greater risk for TLS. Prior to receiving KYPROLIS, ensure that patients are well hydrated. Monitor for evidence of TLS during treatment, and manage promptly. Interrupt KYPROLIS until TLS is resolved.

KYPROLIS causes thrombocytopenia with platelet nadirs occurring around Day 8 of each 28-day cycle and recovery to baseline by the start of the next 28-day cycle. In patients with multiple myeloma, 36% of patients experienced thrombocytopenia, including Grade 4 in 10%. Thrombocytopenia following KYPROLIS administration resulted in a dose reduction in 1% of patients and discontinuation of treatment with KYPROLIS in < 1% of patients. Monitor platelet counts frequently during treatment with KYPROLIS. Reduce or interrupt dose as clinically indicated.

Cases of hepatic failure, including fatal cases, have been reported ( < 1%). KYPROLIS can cause elevations of serum transaminases and bilirubin. Withhold KYPROLIS in patients experiencing Grade 3 or greater elevations of transaminases, bilirubin, or other liver enzyme abnormalities until resolved or returned to baseline. After resolution, consider if restarting KYPROLIS is appropriate. Monitor liver enzymes frequently.

KYPROLIS can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. There are no adequate and well-controlled studies in pregnant women using KYPROLIS. Carfilzomib caused embryo-fetal toxicity in pregnant rabbits at doses that were lower than in patients receiving the recommended dose. Females of reproductive potential should be advised to avoid becoming pregnant while being treated with KYPROLIS.

Serious adverse reactions were reported in 45% of patients. The most common serious adverse reactions were pneumonia (10%), acute renal failure (4%), pyrexia (3%), and congestive heart failure (3%). Adverse reactions leading to discontinuation of KYPROLIS occurred in 15% of patients and included congestive heart failure (2%), cardiac arrest, dyspnea, increased blood creatinine, and acute renal failure (1% each).

The most common adverse reactions (incidence = 30%) were fatigue (56%), anemia (47%), nausea (45%), thrombocytopenia (36%), dyspnea (35%), diarrhea (33%), and pyrexia (30%).

Since dialysis clearance of KYPROLIS concentrations has not been studied, the drug should be administered after the dialysis procedure.

Full prescribing information is available at http://www.kyprolis.com.

About Stivarga® (regorafenib) Tablets

In the United States, Stivarga is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. It is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

Stivarga is an inhibitor of multiple kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.

For full prescribing information, including BOXED WARNING, visit www.stivarga-us.com.

Important Safety Information For Stivarga® (regorafenib) Tablets

WARNING: HEPATOTOXICITY

Severe and sometimes fatal hepatotoxicity has been observed in clinical trials.
Monitor hepatic function prior to and during treatment.
Interrupt and then reduce or discontinue Stivarga for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.
Severe drug-induced liver injury with fatal outcome occurred in 0.3% of 1200 Stivarga-treated patients across all clinical trials. In metastatic colorectal cancer (mCRC), fatal hepatic failure occurred in 1.6% of patients in the Stivarga arm and in 0.4% of patients in the placebo arm; all the patients with hepatic failure had metastatic disease in the liver. In gastrointestinal stromal tumor (GIST), fatal hepatic failure occurred in 0.8% of patients in the Stivarga arm.

Obtain liver function tests (ALT, AST, and bilirubin) before initiation of Stivarga and monitor at least every 2 weeks during the first 2 months of treatment. Thereafter, monitor monthly or more frequently as clinically indicated. Monitor liver function tests weekly in patients experiencing elevated liver function tests until improvement to less than 3 times the upper limit of normal (ULN) or baseline values. Temporarily hold and then reduce or permanently discontinue Stivarga, depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis.

Stivarga caused an increased incidence of hemorrhage. The overall incidence (Grades 1-5) was 21% and 11% with Stivarga vs 8% and 3% with placebo in mCRC and GIST patients, respectively. Fatal hemorrhage occurred in 4 of 632 (0.6%) Stivarga-treated patients and involved the respiratory, gastrointestinal, or genitourinary tracts. Permanently discontinue Stivarga in patients with severe or life-threatening hemorrhage and monitor INR levels more frequently in patients receiving warfarin.

Stivarga caused an increased incidence of hand-foot skin reaction (HFSR) (also known as palmar-plantar erythrodysesthesia [PPE]) and severe rash, frequently requiring dose modification. The overall incidence was 45% and 67% with Stivarga vs 7% and 12% with placebo in mCRC and GIST patients, respectively. Incidence of Grade 3 HFSR (17% vs 0% in mCRC and 22% vs 0% in GIST), Grade 3 rash (6% vs < 1% in mCRC and 7% vs 0% in GIST), serious adverse reactions of erythema multiforme (0.2% vs 0% in mCRC), and Stevens-Johnson syndrome (0.2% vs 0% in mCRC) was higher in Stivarga-treated patients. Toxic epidermal necrolysis occurred in 0.17% of 1200 Stivarga-treated patients across all clinical trials. Withhold Stivarga, reduce the dose, or permanently discontinue depending on the severity and persistence of dermatologic toxicity.

Stivarga caused an increased incidence of hypertension (30% vs 8% in mCRC and 59% vs 27% in GIST with Stivarga vs placebo, respectively). Hypertensive crisis occurred in 0.25% of 1200 Stivarga-treated patients across all clinical trials. Do not initiate Stivarga until blood pressure is adequately controlled. Monitor blood pressure weekly for the first 6 weeks of treatment and then every cycle, or more frequently, as clinically indicated. Temporarily or permanently withhold Stivarga for severe or uncontrolled hypertension.

Stivarga increased the incidence of myocardial ischemia and infarction in mCRC (1.2% with Stivarga vs 0.4% with placebo). Withhold Stivarga in patients who develop new or acute cardiac ischemia or infarction, and resume only after resolution of acute cardiac ischemic events if the potential benefits outweigh the risks of further cardiac ischemia.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS) occurred in 1 of 1200 Stivarga-treated patients across all clinical trials. Perform an evaluation for RPLS in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Confirm the diagnosis of RPLS with MRI and discontinue Stivarga in patients who develop RPLS.

Gastrointestinal perforation or fistula occurred in 0.6% of 1200 patients treated with Stivarga across clinical trials. In GIST, 2.1% (4/188) of Stivarga-treated patients developed gastrointestinal fistula or perforation: of these, 2 cases of gastrointestinal perforation were fatal. Permanently discontinue Stivarga in patients who develop gastrointestinal perforation or fistula.

Treatment with Stivarga should be stopped at least 2 weeks prior to scheduled surgery. Resuming treatment after surgery should be based on clinical judgment of adequate wound healing. Stivarga should be discontinued in patients with wound dehiscence.

Stivarga can cause fetal harm when administered to a pregnant woman. Use effective contraception during treatment and up to 2 months after completion of therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Stivarga, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

The most frequently observed adverse drug reactions ( = 30%) in Stivarga-treated patients vs placebo-treated patients in mCRC, respectively, were: asthenia/fatigue (64% vs 46%), decreased appetite and food intake (47% vs 28%), HFSR/PPE (45% vs 7%), diarrhea (43% vs 17%), mucositis (33% vs 5%), weight loss (32% vs 10%), infection (31% vs 17%), hypertension (30% vs 8%), and dysphonia (30% vs 6%).

The most frequently observed adverse drug reactions ( = 30%) in Stivarga-treated patients vs placebo-treated patients in GIST, respectively, were: HFSR/PPE (67% vs 15%), hypertension (59% vs 27%), asthenia/fatigue (52% vs 39%), diarrhea (47% vs 9%), mucositis (40% vs 8%), dysphonia (39% vs 9%), infection (32% vs 5%), decreased appetite and food intake (31% vs 21%), and rash (30% vs 3%).

For full prescribing information, including BOXED WARNING, visit www.stivarga-us.com.

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com. Onyx Pharmaceuticals is on Twitter. Sign up to follow our Twitter feed @OnyxPharm at http://twitter.com/OnyxPharm.

Forward-Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection and Stivarga® (regorafenib) tablets. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, filed with the Securities and Exchange Commission under the heading "Risk Factors" for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Contacts:



Investors

Amy Figueroa

Senior Director, Investor Relations

(650) 266-2398



Media

Lori Melançon

Senior Director, Corporate Communications

(650) 266-2394

ONXX Monthly Charts: My Favorite Pharma Co.......Best of Breed.....Number one in the Cancer Drug Sector......

Nice Breakout in June 2012 above 2004 & 2007 resistance levels.........sweet breakout in March 2013 above Sept. & Oct. 2012 resistance levels.........

Riding in the very Bullish Upper Bollinger Band Channel between Upper BB resistance & MA(10) Support.......been trading in this channel for a yr. straight......as you can see on this chart @ the end of 2011 & the beginning of 2012 MA(20)/Middle Bollinger Band support was tested & held.......as long as ONXX stays above the Middle BB the Uptrend will continue......

Hitting the big 100 resistance level.....break it & it's SHOWTIME!..........fail to break 100 & turn it into support & a pullback to MA(10) @ 82.10 should follow.......as this chart shows ONXX has a history of running for multiple months.......the current run is working on the 3rd green month in a row........ONXX could very easily break 100 & run much higher before pulling back......

MACD is signaling a move higher & Accum/Dist & OBV are showing massive accumulation........Full Sto just entered the Power zone & looking @ past performance Fast Sto should be able to keep charging in the Power Zone.........

ONXX on break 100 & continue to run to new highs radar............$$$

Onyx Pharmaceuticals to Report First Quarter 2013 Financial Results After Market on May 7, 2013



http://ih.advfn.com/p.php?pid=nmona&article=57196695&symbol=ONXX

Onyx Pharmaceuticals Announces Proteasome Inhibitor Data Presentations at 14th International Myeloma Workshop

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today highlighted the presentation of three studies, among several, from its proteasome inhibitor franchise at the 14th International Myeloma Workshop (IMW), April 3-7, 2013, in Kyoto, Japan. New data will be presented on carfilzomib in high-risk-smoldering myeloma and on oprozomib in hematologic malignances.

"The results being presented at the IMW continue to build our clinical understanding of carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral proteasome inhibitor in early development," said Pablo Cagnoni, M.D., Executive Vice President, Global Research & Development and Technical Operations, Onyx Pharmaceuticals. "Onyx is committed to the continued development of both these proteasome inhibitors in multiple myeloma, as well as other hematologic malignancies and to bringing these therapies to patients globally as quickly as possible."

Carfilzomib

Clinical and Correlative (Phase II) Pilot Study - Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (Dex) in High Risk Smoldering Multiple Myeloma ("Early Myeloma")
•Dr. Ola Landgren, National Cancer Institute (NCI)
•Saturday, April 6, 8:00-8:12 a.m. JST (Friday, April 5, 7:00-7:12 p.m. ET)
•Plenary Session 1

Treatment (tx) with CRd -- carfilzomib (CFZ), lenalidomide (LEN) and low-dose dexamethasone (dex) -- for elderly patients (pts) with newly diagnosed multiple myeloma (NDMM) enrolled in a phase (Ph) 1/2 study
•Dr. Andrzej Jakubowiak, University of Chicago Medical Center
•Saturday, April 6, 8:48-9:00 a.m. JST (Friday, April 5, 7:48-8:00 p.m. ET)
•Plenary Session 1

Oprozomib

Oprozomib Treatment in Patients With Hematologic Malignancies: Updated Results From a Phase 1b/2 Trial
•Dr. Jonathan Kaufman, Winship Cancer Institute
•Thursday, April 4, 5:00-9:00 p.m., Friday-Saturday, April 5-6 10:00 a.m.-4:00 p.m. JST (Thursday, April 4 4:00-8:00 a.m. ET, Thursday-Friday, April 4-5 9:00 p.m.-3:00 a.m. ET)
•Poster # P-225
•Abstract # 427

Important Indication and Safety Information Regarding Kyprolis® (carfilzomib) for Injection

On July 20, 2012, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Kyprolis® (carfilzomib) for Injection for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval was based on response rate. Clinical benefit, such as improvement in survival or symptoms, has not been verified.

Safety data have been evaluated in 526 patients with relapsed and/or refractory multiple myeloma who received single-agent Kyprolis. There were 37 deaths in the phase 2 studies, or 7% of patients. The most common causes of death, other than disease progression, were cardiac (5 patients), end-organ failure (4 patients), and infection (4 patients). Important warnings and precautions include cardiac arrest, congestive heart failure, myocardial ischemia; pulmonary hypertension, pulmonary complications, infusion reactions, tumor lysis syndrome, thrombocytopenia, hepatic toxicity and embryo-fetal toxicity.

Death due to cardiac arrest has occurred within a day of Kyprolis administration. Patients with New York Heart Association Class III and IV heart failure, myocardial infarction in the preceding 6 months, and conduction abnormalities uncontrolled by medications were not eligible for the clinical trials. These patients may be at greater risk for cardiac complications.

Pulmonary arterial hypertension (PAH) was reported in 2% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients. Dyspnea was reported in 35% of patients enrolled in clinical trials. Grade 3 dyspnea occurred in 5%; no Grade 4 events, and 1 death (Grade 5) was reported.

Infusion reactions, characterized by a spectrum of systemic symptoms including fever, chills, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina can occur immediately following or up to 24 hours after administration of Kyprolis. Administration of dexamethasone prior to Kyprolis reduces the incidence and severity of reactions. Tumor lysis syndrome (TLS) occurred following Kyprolis administration in < 1% of patients. Patients with multiple myeloma and a high tumor burden should be considered to be at greater risk for TLS.

Thrombocytopenia following Kyprolis administration resulted in a dose reduction in 1% of patients and discontinuation of treatment with Kyprolis in < 1% of patients.

Cases of hepatic failure, including fatal cases, have been reported (< 1%). Kyprolis can cause elevations of serum transaminases and bilirubin.

There are no adequate and well-controlled studies in pregnant women using Kyprolis. Females of reproductive potential should be advised to avoid becoming pregnant while being treated with Kyprolis. The most common serious adverse reactions were pneumonia, acute renal failure, pyrexia, and congestive heart failure. The most common adverse reactions (incidence of 30% or greater) observed in clinical trials of patients with multiple myeloma were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia. Serious adverse reactions were reported in 45% of patients.

Full prescribing information is available at http://www.onyx.com.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(1) Worldwide, more than 220,000 people are living with multiple myeloma and approximately 100,000 new cases are diagnosed annually.(2)

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.

Forward-Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Kyprolis (carfilzomib) or oprozomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission under the heading "Risk Factors" for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(1) American Cancer Society, Cancer Facts & Figures 2012

(2) National Analysts & Kantar Health Market Research

ONXX Chart......been on major beast mode.......starting to top out.........cool name......ONYX!.........love that name...........$$$

Nice news ONXX ding..ding..ding

Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment


WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Feb. 25, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga® (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.1 Stivarga was approved by the FDA in September 2012 for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.1

(Photo: http://photos.prnewswire.com/prnh/20130225/NY62678 )

"The FDA's decision marks the second approval for Stivarga – first in metastatic colorectal cancer last year and now in locally advanced, unresectable or metastatic GIST, where there is a high unmet medical need for patients who have exhausted all approved treatment options," said Pamela A. Cyrus, MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. "These regulatory milestones underscore Bayer's commitment to deliver effective products for difficult-to-treat cancers."

Stivarga is a Bayer compound developed by Bayer and jointly promoted by Bayer and Onyx in the United States. In 2011, Bayer entered into an agreement with Onyx, under which Onyx receives a royalty on all global net sales of Stivarga in oncology.

The approval of Stivarga in GIST is based on data from the pivotal Phase III GRID (GIST – Regorafenib In Progressive Disease) trial, which showed that Stivarga plus best supportive care (BSC) statistically significantly improved progression-free survival (PFS) compared to placebo plus BSC (HR=0.27 [95% CI 0.19-0.39], p<0.0001) in patients with locally advanced, unresectable or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate.1 The median PFS was 4.8 months in the Stivarga arm versus 0.9 months in the placebo arm (p<0.0001). There was no statistically significant difference in overall survival at the time of the planned interim analysis based on 29% of the total events for the final analysis. At the time of disease progression as assessed by central review, the study blind was broken and all patients were offered the opportunity to take Stivarga at the investigator's discretion. Fifty-six (85%) patients randomized to placebo and 41 (31%) patients randomized to Stivarga received open-label Stivarga.1

The most frequently observed adverse drug reactions (= 30%) in Stivarga-treated patients vs. placebo-treated patients in GIST, respectively, were: hand-foot skin reaction (HFSR) / palmar-plantar erythrodysesthesia (PPE), hypertension, asthenia/fatigue, diarrhea, mucositis, dysphonia, infection, decreased appetite and food intake, and rash. The Stivarga label includes a boxed warning citing the risk of hepatotoxicity. Severe and sometimes fatal hepatotoxicity has been observed in clinical trials.1

"While great progress has been made in the treatment of GIST since the introduction of kinase inhibitors as effective therapies for this orphan disease, we have been looking for additional, effective treatments for GIST patients whose disease worsens despite currently approved therapies," said George D. Demetri, MD, Principal Investigator of the GRID study and Director of the Center for Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute in Boston, MA. "These data show that regorafenib can slow disease progression in patients who are no longer responding to other approved therapies and may provide another avenue for GIST patients who would otherwise have no FDA-approved treatment option."

About Gastrointestinal Stromal Tumor (GIST)
GIST is the most common form of sarcoma (a type of cancer that develops from certain tissues, like bone or muscle) involving the gastrointestinal tract.2 In the United States, it is estimated that there are approximately 4,000-5,000 new cases of GIST diagnosed each year, of which about 1,500 have already metastasized at diagnosis.2,3 GIST may not cause any symptoms and may be found incidentally when the doctor is looking for other problems.3

About the GRID Study
GRID was a randomized, double-blind, placebo-controlled, multi-center, cross-over Phase III study of regorafenib for the treatment of GIST. It randomized 199 patients who had been previously treated with imatinib mesylate and sunitinib malate. Patients were randomized in a 2:1 ratio to receive either regorafenib plus BSC or placebo plus BSC to evaluate efficacy and safety. Treatment cycles consisted of 160 mg regorafenib (or matching placebo) once daily for three weeks on / one week off plus BSC. Patients continued therapy until disease progression or unacceptable toxicity. The primary endpoint was PFS, and the key secondary outcome measure was OS. The safety and tolerability of the two treatment groups were also compared.4

About Stivarga (regorafenib)
Stivarga is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.1 It is also indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.1

Stivarga is an inhibitor of multiple kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.1

Stivarga was developed under the Fast Track program and received priority review designations for locally advanced, unresectable or metastatic GIST and mCRC from the FDA. These designations are granted by the FDA to expedite the development and review of drugs to treat serious diseases and fill an unmet medical need (fast track), and given to drugs that provide a treatment where no adequate therapy exists (priority review).

For full prescribing information, including BOXED WARNING, visit www.stivarga-us.com. Bayer offers patient assistance through the Bayer REACH® (Resources for Expert Assistance and Care Helpline) program. Patients may contact the REACH Program at 1-866-639-2827 for additional information.

WARNING: HEPATOTOXICITY:

Severe and sometimes fatal hepatotoxicity has been observed in clinical trials.
Monitor hepatic function prior to and during treatment.
Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.
Severe drug-induced liver injury with fatal outcome occurred in 0.3% of 1200 STIVARGA-treated patients across all clinical trials. In metastatic colorectal cancer (mCRC), fatal hepatic failure occurred in 1.6% of patients in the STIVARGA arm and in 0.4% of patients in the placebo arm; all the patients with hepatic failure had metastatic disease in the liver. In gastrointestinal stromal tumor (GIST), fatal hepatic failure occurred in 0.8% of patients in the STIVARGA arm.

Obtain liver function tests (ALT, AST, and bilirubin) before initiation of STIVARGA and monitor at least every 2 weeks during the first 2 months of treatment. Thereafter, monitor monthly or more frequently as clinically indicated. Monitor liver function tests weekly in patients experiencing elevated liver function tests until improvement to less than 3 times the upper limit of normal (ULN) or baseline values. Temporarily hold and then reduce or permanently discontinue STIVARGA, depending on the severity and persistence of hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis.

STIVARGA caused an increased incidence of hemorrhage. The overall incidence (Grades 1-5) was 21% and 11% with STIVARGA vs 8% and 3% with placebo in mCRC and GIST patients, respectively. Fatal hemorrhage occurred in 4 of 632 (0.6%) STIVARGA-treated patients and involved the respiratory, gastrointestinal, or genitourinary tracts. Permanently discontinue STIVARGA in patients with severe or life-threatening hemorrhage and monitor INR levels more frequently in patients receiving warfarin.

STIVARGA caused an increased incidence of hand-foot skin reaction (HFSR) (also known as palmar-plantar erythrodysesthesia [PPE]) and severe rash, frequently requiring dose modification. The overall incidence was 45% and 67% with STIVARGA vs 7% and 12% with placebo in mCRC and GIST patients, respectively. Incidence of Grade 3 HFSR (17% vs 0% in mCRC and 22% vs 0% in GIST), Grade 3 rash (6% vs <1% in mCRC and 7% vs 0% in GIST), serious adverse reactions of erythema multiforme (0.2% vs 0% in mCRC), and Stevens-Johnson syndrome (0.2% vs 0% in mCRC) was higher in STIVARGA-treated patients. Toxic epidermal necrolysis occurred in 0.17% of 1200 STIVARGA-treated patients across all clinical trials. Withhold STIVARGA, reduce the dose, or permanently discontinue depending on the severity and persistence of dermatologic toxicity.

STIVARGA caused an increased incidence of hypertension (30% vs 8% in mCRC and 59% vs 27% in GIST with STIVARGA vs placebo, respectively). Hypertensive crisis occurred in 0.25% of 1200 STIVARGA-treated patients across all clinical trials. Do not initiate STIVARGA until blood pressure is adequately controlled. Monitor blood pressure weekly for the first 6 weeks of treatment and then every cycle, or more frequently, as clinically indicated. Temporarily or permanently withhold STIVARGA for severe or uncontrolled hypertension.

STIVARGA increased the incidence of myocardial ischemia and infarction (1.2% with STIVARGA vs 0.4% with placebo). Withhold STIVARGA in patients who develop new or acute cardiac ischemia or infarction, and resume only after resolution of acute cardiac ischemic events if the potential benefits outweigh the risks of further cardiac ischemia.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS) occurred in 1 of 1200 STIVARGA-treated patients across all clinical trials. Confirm the diagnosis of RPLS with MRI and discontinue STIVARGA in patients who develop RPLS.

Gastrointestinal perforation or fistula occurred in 0.6% of 1200 patients treated with STIVARGA across clinical trials. In GIST, 2.1% (4/188) of STIVARGA-treated patients developed gastrointestinal fistula or perforation: of these, 2 cases of gastrointestinal perforation were fatal. Permanently discontinue STIVARGA in patients who develop gastrointestinal perforation or fistula.

Treatment with STIVARGA should be stopped at least 2 weeks prior to scheduled surgery. Resuming treatment after surgery should be based on clinical judgment of adequate wound healing. STIVARGA should be discontinued in patients with wound dehiscence.

STIVARGA can cause fetal harm when administered to a pregnant woman. Use effective contraception during treatment and up to 2 months after completion of therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from STIVARGA, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

The most frequently observed adverse drug reactions (=30%) in STIVARGA-treated patients vs placebo-treated patients in mCRC, respectively, were: asthenia/fatigue (64% vs 46%), decreased appetite and food intake (47% vs 28%), HFSR/PPE (45% vs 7%), diarrhea (43% vs 17%), mucositis (33% vs 5%), weight loss (32% vs 10%), infection (31% vs 17%), hypertension (30% vs 8%), and dysphonia (30% vs 6%).

The most frequently observed adverse drug reactions (=30%) in STIVARGA-treated patients vs placebo-treated patients in GIST, respectively, were: HFSR/PPE (67% vs 15%), hypertension (59% vs 27%), asthenia/fatigue (52% vs 39%), diarrhea (47% vs 9%), mucositis (40% vs 8%), dysphonia (39% vs 9%), infection (32% vs 5%), decreased appetite and food intake (31% vs 21%), and rash (30% vs 3%).

About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. Bayer's oncology franchise now includes two oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company's approach to research, which prioritizes novel targets and pathways with the potential to transform the way that cancer is treated across tumor types and stages of disease.

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. As a specialty pharmaceutical company, Bayer HealthCare provides products for General Medicine, Hematology, Neurology, Oncology and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.

STIVARGA® is a trademark of Bayer®. Bayer® and the Bayer Cross® are registered trademarks of Bayer.


Forward-Looking Statement
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding results of clinical development, regulatory processes, safety and commercial potential of Stivarga (regorafenib). These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: competition; failures or delays in clinical trials or the regulatory process; Onyx or Bayer, as the case may be, may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for Stivarga; market acceptance and the rate of adoption of Stivarga; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Stivarga; and government regulation. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission, as updated by Onyx's subsequent Quarterly Reports on Form 10-Q, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

References:

1. STIVARGA Prescribing Information, February 2013.

2. Joensuu H. Gastrointestinal stromal tumor (GIST). Annals of Oncology. 2006 September; Volume 17. Available at http://annonc.oxfordjournals.org/content/17/suppl_10/x280.full.pdf+html . Accessed October 19, 2012.

3. American Cancer Society. Gastrointestinal Stromal Tumor (GIST). (Last Revised 2/1/2012). Available at http://www.cancer.org/acs/groups/cid/documents/webcontent/003103-pdf.pdf. Accessed October 12, 2012.

4. Casali, et al. Clinical benefit with regorafenib across subgroups and post progression in patients with advanced gastrointestinal stromal tumors (GIST) after progression on imatinib (IM) and sunitinib (SU): Phase III GRID trial update. 2012 European Society of Medical Oncology; September, 2012. Vienna, Austria.

Nice ONXX looking great today.

Good call on this one.

ONXX Onyx Pharmaceuticals Soars 5%, Hits New Year High; Adding to 144% Gains in 12 Months
BY MidnightTrader 2:46 PM ET 09/17/2012

http://stockcharts.com/h-sc/ui?s=onxx

Onyx Pharmaceuticals, Inc. (ONXX) is up 5% at $80.50, backing off a new year high of $80.64. The NASDAQ OMX Group, Inc. (NDAQ) announced today the results of the quarterly re-ranking of the NASDAQ Q-50 IndexSM (NXTQ), which will become effective prior to market open on Monday, September 24, 2012. ONXX is among nine securities that will be added to the index.

Also, Seeking Alpha said it was among the top biotech firms to get HF money in current quarter.

ONXX has increased 144% in the last 12 months.

You short?

Who is buying this junk plus $70......


$45 in a month IMO, the earnings report is alarming, this company does nothing but lose money hand over fist.

Insiders sell for a variety of reasons. Some are long planned sales. The stock price has gone up a lot so it's normal to see some selling. The fact is institutional support is very strong, revenues will increase dramatically with another FDA approved drug, analysts have upgraded and increased their price targets and there is always a chance of a buyout. The fact that there is some insider selling means nothing.

You may want to wake up, if insiders are selling why are you holding? Ask yourself that question

Yawn